Notes

Progress and tendencies associated with photodynamic remedy: Coming from conventional photosensitizers in order to AIE-based photosensitizers.
There is no unequivocal opinion regarding the safety of statin in patients with hypothyroidism. However, based on some new data, it can be assumed that hypothyroidism, even in a stage of compensation, may cause muscle damage in patients receiving statins. As part of this study, this hypothesis was tested, and was confirmed.

To study the possibility of muscle damage and the nature of muscle metabolism in patients with compensated hypothyroidism who takes statin.

The study is transverse and observational with the inclusion of 120 women, subdivided on three groups (n=40). The main group of patients with hypothyroidism who took statins (group 1) was compared with two control groups, including those who took statins without hypothyroidism (group 2), and who did not take statins with hypothyroidism (group 3).

Patients taking statins and have compensated hypothyroidism are more likely to develop complaints of muscle pain, which are often associated with the elevation of muscle lesion markers, as well as the d biochemical parameters of muscle metabolism (especially the level of CPK).
The feasibility of using molecular genetic markers for the diagnosis of thyroid tumors and the impact on the prognosis of thyroid cancer are being actively investigated. The most interesting are genes, the detection of which is associated not only with thyroid cancer, but also with a more aggressive course of the disease. The ability to diagnose the molecular profile of minimally invasive methods with the study of freely circulating DNA tumor tissue in blood plasma is a modern trend of medicine.

to evaluate the frequency of somatic mutations in the «hot spots» of BRAF, KRAS, KRAS, EIF1AX and TERT genes in circulating DNA of blood plasma.

Samples of DNA, extracted from the removed tumor and non-tumor thyroid tissue, were tested for the presence of somatic mutations in hot spots of the genes BRAF, KRAS, NRAS, TERT, and EIF1AX and then in identifying mutations and testing appropriate samples of free circulating DNA in blood plasma.

mutations in the» hot spots «of the BRAF gene (exon 15, codon area 600-601) were found in 54 patients, mutations in the» hot spots « of the NRAS gene (exon 3, codon 61) – in 12 patients; mutations in the hot spots of the KRAS, TERT and EIF1AX genes were not detected. In freely circulating blood plasma DNA, BRAF gene mutations were detected in 1 case, NRAS gene mutations were detected in 1 case.

the use of freely circulating DNA of blood plasma in the testing of the studied sample did not show the feasibility for the diagnosis of thyroid tumors.
the use of freely circulating DNA of blood plasma in the testing of the studied sample did not show the feasibility for the diagnosis of thyroid tumors.The article «Hypoglycemic syndrome in patients with monoclonal gammopathy» published by Solovyev MV, Yukina MY, Troshina EA in Problems of Endocrinology 2020;65(6) (doi 10.14341/probl12266) contains wrong data in «Conflict of interests» section. Correct information is «Manuscript preparation and publication was supported by the Russian Science Foundation (project No. 17-75-30035). The information given in the article about the sources of funding should not have any significant effect on the perception of information by readers and / or interpretation of the data presented. The authors regret the incorrect information in a previously published article.In January 2020, the famous scientist biochemist-endocrinologist, MD, professor Nikolay P. Goncharov turned 85 years old. Nikolay P. Goncharov — one of the leading experts in the field of biochemical endocrinology and hormonal analysis; he developed and introduced in the framework of the Human Reproduction program an experimental model for evaluating the pharmacokinetics, mechanism of action, efficacy and safety of new steroid drugs and regulators of endocrine secretion of steroid hormones. The editorial board of the journal “Problems of Endocrinology” congratulates NP Goncharov on his anniversary, wishes him good health, success, prosperity, vitality, fortitude and many more years of fruitful activity.
Spontaneous recovery of the hypothalamic–pituitary–gonadal (HPG) axis after cessation of testosterone replacement therapy or after male contraception may take up to 24 months. There is insufficient data on the duration of recovery of HPG axis after abuse of androgenic anabolic steroids (AAS). AAS users use post-cycle therapy (PCT) to restore HPG axis, the effectiveness of which is unknown and needs further investigation.

To evaluate the recovery of HPG axis in men, AAS users, after a 3-month of cessation of their use and after PCT.

An observational, single-center, prospective, sampling, open, uncontrolled study was conducted among male AAS users. While using of AAS and 3 months after the refusal of their administration and PCT, the clinical symptoms of hypogonadism were evaluated, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (Tt), prolactin, estradiol, inhibin B, thyroid-stimulating hormone (TSH) were determined. The scheme of rehabilitation therap and type of AAS on the restoration of HPG axis was established. The level of inhibin B may serve as a marker for the restoration of spermatogenic epithelium.
The registry is the main source of information about patients with acromegaly for assessing the quality of medical care, effectiveness of treatment, determining the compliance of real clinical practice with existing standards and patient management protocols.

To evaluate epidemiological, demographic and clinical characteristics of acromegaly in Russian Federation and effectiveness of treatment modalities.

The object of the study was the database of the united Russian registry of patients with pituitary tumors with specific analysis of patients with acromegaly only. see more We analyzed the data of 4114 patients with acromegaly stored on the online system in February 2019.

Based on the data 32% of patients had complete clinical and laboratory remission of acromegaly; the percentage of patients with no remission was 68%, among them 22.5% had significant improvements in clinical symptoms and a decrease in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) without IGF-1 normalization. The average age of patients at the onset of the disease was 42.
My Website: https://www.selleckchem.com/products/jbj-09-063-hydrochloride.html